Introduction
============

Prostate cancer (PCa) is the second-most frequently diagnosed cancer in males around the world. It is also one of the leading causes of cancer death among men of all races.[@b1-ott-9-1033] Its etiology has remained unclear, and few risk factors have been established for PCa other than older age, a positive family history, and race.[@b2-ott-9-1033] Some previous epidemiological studies suggested that low serum levels of the vitamin D receptor (VDR) might be a risk factor for PCa.[@b3-ott-9-1033],[@b4-ott-9-1033] Such low levels could be recognized by 1 alpha, 25-dihydroxyvitamin D~3~ -- active form of vitamin D -- and its analogs, and through the interaction between these substances, the tumor cell growth cycle could be fixed in the G1 phase, leading to stagnation of the tumor cells.[@b5-ott-9-1033] However, the mechanism responsible for reduced VDR expression is still not known.

Recently, some studies have shown that VDR gene polymorphisms have functional significance for the stability of mRNA and the protein translation efficiency and may be responsible for the reduced VDR level.[@b6-ott-9-1033],[@b7-ott-9-1033] The human VDR gene is located on chromosome 12q13.11 and consists of 14 exons spanning \~75 kb.[@b8-ott-9-1033],[@b9-ott-9-1033] It is highly polymorphic with at least 618 variants reported, most of which are either undetectable or present at a low frequency in the general population, according to the dbSNP database.[@b10-ott-9-1033]

TaqI is one of the most extensively studied SNP and is located in exon 9 of the VDR gene. Several previous studies have suggested that TaqI might alter VDR mRNA levels through regulation of mRNA stability and be associated with a PCa risk.[@b11-ott-9-1033] A number of case--control studies were conducted to investigate the association between the TaqI and the risk of PCa. However, existing evidence is inadequate to draw robust conclusions because the results are not consistent and most studies were generally small. Three published meta-analyses have been reported, but no positive conclusions were given.[@b11-ott-9-1033]--[@b13-ott-9-1033] Subsequently, four new studies have provided additional data on the association between TaqI and PCa risk.[@b14-ott-9-1033]--[@b17-ott-9-1033] Therefore, to shed light on these inconclusive findings, we used the new data to conduct a meta-analysis to revisit the association between the VDR TaqI polymorphism and the risk and characteristics of PCa.

Materials and methods
=====================

Search strategy
---------------

We searched the PubMed and Web of Science databases up to September 8, 2015, for relevant studies about the association of VDR gene TaqI polymorphism and PCa without language restrictions. The search terms included polymorphism, vitamin D receptor, vitamin D~3~ receptor, 1,25-dihydroxyvitamin D~3~ receptor, calcitriol receptor, VDR, and PCa, prostate neoplasm, prostate tumor, prostate carcinoma, or prostatic neoplasm.

Inclusion/exclusion criteria
----------------------------

The title, abstract, and full text of the candidate studies were independently screened by two reviewers. A study was included when all of the following criteria were met: 1) A nonfamilial case--control and cohort study that examined the association between VDR polymorphism and PCa risk with genotyping data for TaqI was included. 2) A study that used men with benign prostatic hyperplasia was included, but a study based on family or pedigree was excluded because of consideration of disease specificity and genetic linkage. 3) A study on localized PCa: confined within the prostate, stages T1--T2 or stages A--B; advanced PCa: extraprostatic or metastatic cancer involving lymph nodes or other organs, stages T3--T4 or stages C--D was included. 4) A study that had complete data or data that could be used to calculate an odds ratio (OR) and a 95% confidence interval (95% CI) was included. 5) A study that used men with benign prostatic hyperplasia as a control was included. 6) A case-only study or a study that had incomplete data for the control group was excluded.

Data extraction
---------------

Information was carefully extracted from all eligible publications by two independent reviewers (Fei and Liu), based on the aforementioned inclusion criteria. Any disagreements were arbitrated by discussion with a third reviewer (Wu). The following data were collected from each study: the first author's surname, the year of publication, the study location, the ethnicity, the source of the controls, the laboratory methods used to detect VDR TaqI polymorphism, and the number of cases and controls. The ethnic groups were mainly defined as Caucasian, Asian, and African. For analysis of the risk factors associated with PCa, we divided the clinical stages and Gleason score into the following two groups: a local group and an advanced group as described previously, Gleason score \<7 and ≥7 groups.

Quality assessment
------------------

We used the Newcastle--Ottawa Scale (NOS) to assess the quality of each eligible study. When an item was met, the study got one point. The NOS runs from zero to nine points. A study was considered high quality if it received more than four points.[@b18-ott-9-1033]

Statistical analysis
--------------------

The strength of the association between TaqI T/t polymorphism and the risk of PCa was indicated by an OR with a 95% CI. The statistical significance of the pooled OR was assessed with the *Z*-test and a *P*-value of \<0.05 was considered significant. A chi-square-based *Q*-test was conducted to measure the heterogeneity of eligible studies, and the heterogeneity was considered significant if the *P*-value for heterogeneity test was \<0.05. Subgroup analyses were conducted to identify the possible variables or characteristics that moderated the obtained results. A sensitivity analysis in which one study was excluded at a time was conducted to evaluate the influence of an individual study based on the results. Begg's funnel plot and Egger's regression test were used to evaluate the publication bias (no publication bias was indicated by a two-sided *P*-value ≥0.05). All analyses were conducted using the Stata version 11.0 software (StataCorp LP, College Station, TX, USA), and a two-sided *P*-value ≥0.05 indicated no significance.

Results
=======

Literature search
-----------------

The study selection process is shown in [Figure 1](#f1-ott-9-1033){ref-type="fig"}. The primary literature search identified 507 studies. After the titles and abstracts were screened, 387 studies were excluded; 78 were reviews, meta-analyses, and letters. The full texts of the remaining 42 studies were evaluated further. As a result, 27 studies were included in the meta-analysis.[@b3-ott-9-1033],[@b4-ott-9-1033],[@b6-ott-9-1033],[@b14-ott-9-1033]--[@b17-ott-9-1033],[@b19-ott-9-1033]--[@b38-ott-9-1033]

Characters and assessments of involved studies
----------------------------------------------

The 27 eligible studies included 12,276 cases and 13,506 controls and were assessed by the NOS ([Table S1](#SD1-ott-9-1033){ref-type="supplementary-material"}). Each had a score of \>4, which means that all the studies had high quality. The distribution of the VDR gene TaqI polymorphism genotype and allele is shown in [Tables 1](#t1-ott-9-1033){ref-type="table"} and [S2](#SD2-ott-9-1033){ref-type="supplementary-material"}.

### Meta-analysis of the association of VDR gene TaqI polymorphism with PCa risk

The pooled results of 27 relevant studies on the correlation between TaqI polymorphisms and the risk of PCa are presented in [Table 2](#t2-ott-9-1033){ref-type="table"} and [Figure 2](#f2-ott-9-1033){ref-type="fig"}. The outcome indicated that TaqI genetic polymorphism was significantly associated with the risk of PCa (T vs t allele: OR =1.11, 95% CI =1.03--1.21, *P*=0.008; TT vs tt: OR =1.19, 95% CI =1.01--1.42, *P*=0.040; TT + Tt vs tt: OR =1.18, 95% CI =1.02--1.38, *P*=0.031).

### Meta-analysis of the association of VDR gene TaqI polymorphism with PCa risk in different populations

A previous study showed that ethnicity was a primary risk factor for PCa.[@b2-ott-9-1033] In order to draw attention to this point, an stratified analysis of ethnicity was performed,[@b3-ott-9-1033],[@b6-ott-9-1033],[@b14-ott-9-1033]--[@b17-ott-9-1033],[@b19-ott-9-1033]--[@b29-ott-9-1033],[@b31-ott-9-1033]--[@b33-ott-9-1033],[@b35-ott-9-1033]--[@b38-ott-9-1033] and the pooled results indicated that TaqI genetic polymorphism in the VDR gene was closely linked to the pathogenesis of PCa among Asian populations (T vs t allele: OR =1.11, 95% CI =1.03--1.21, *P*=0.008; TT/Tt vs tt: OR =1.93, 95% CI =1.02--3.66, *P*=0.043) ([Table 3](#t3-ott-9-1033){ref-type="table"} and [Figure 3](#f3-ott-9-1033){ref-type="fig"}). A sensitivity analyses indicated that an independent study by Jingwi et al was the principal reference for heterogeneity of TaqI polymorphism in the African population.[@b17-ott-9-1033] After the exclusion of this study, the heterogeneity was effectively decreased or was eliminated, and the outcome showed that no statistical significance was found among African or Caucasian populations.

### Meta-analysis of the association of VDR gene TaqI polymorphism with PCa risk in different tumor stages and Gleason score

We also performed a stratified analysis based on the tumor stage and the Gleason score to delineate the association of VDR gene TaqI polymorphism with PCa risk in more detail. As shown in [Table 4](#t4-ott-9-1033){ref-type="table"} and [Figure 4](#f4-ott-9-1033){ref-type="fig"}, in the tumor stage stratified analysis, the pooled results showed no significant difference in the genetic polymorphism between local tumor group and the control group or between the local tumor group and the advanced tumor group. However, the genotypes TT and TT/Tt were significantly higher in the advanced PCa group compared to the control group (T vs t allele: OR =1.20, 95% CI =1.01--1.42, *P*=0.040; TT vs tt: OR =1.34, 95% CI =1.08--1.67, *P*=0.009; TT/Tt vs tt: OR =1.28, 95% CI =1.05--1.56, *P*=0.015).

In the Gleason score stratified analysis, no statistically significant difference in the distribution of the allele and genotype of TaqI polymorphism was evident (TT/Tt vs tt: OR =1.28, 95% CI =0.52--3.13, *P*=0.584; TT vs Tt/tt: OR =0.79, 95% CI =0.45--1.37, *P*=0.396). However, the number of articles included[@b15-ott-9-1033],[@b27-ott-9-1033],[@b30-ott-9-1033] was too little to draw a robust conclusion. Therefore, further relevant studies should be performed in the future.

Sensitivity analysis
--------------------

Sensitivity analyses were performed by the sequential omission of individual studies for all subjects and stratified analyses. Except for the stratified analyses of the association between TaqI polymorphism and PCa risk in an African population, the corresponding pooled ORs were not materially altered in the other stratified analyses, indicating the robustness of the results of this meta-analysis.

Publication bias assessment
---------------------------

Begg's funnel plot and Egger's test were performed to assess the publication bias in the literature. No evidence of publication bias was found for all analyses. Egger's and Begg's tests were not performed for the Gleason stratified analyses and the stage stratified analyses of TT vs tt in the comparison of local tumor group with the control group and the local tumor group with the advanced tumor group due to the small number of included studies.

Discussion
==========

Various factors contribute to the basic pathology of PCa. Clinical diagnosis of the disease is aided by prostate-specific antigen and biopsy, but none of these methods provide a definitive diagnosis and/or a credible assessment of progression of the disease.[@b39-ott-9-1033],[@b40-ott-9-1033] Recently, genetic susceptibility to cancer has been a focus of research by the scientific community. The development and progression of PCa are influenced by vitamin D synthesis.[@b3-ott-9-1033] Therefore, the polymorphism of genes that encode key proteins involved in vitamin D synthesis and metabolism has been chosen as primary candidate genes for PCa susceptibility. Currently, a growing number of studies that have revealed polymorphic variants of the VDR gene were associated with the etiology of PCa. In this meta-analysis, we have analyzed the role of the VDR gene TaqI polymorphism in PCa, which is located in exon 9 and is responsible for the stability of the mRNA. We found that a variant TaqI allele (t) was significantly correlated with a reduced risk of PCa, suggesting it might be a protective factor for PCa, which was consistent with a previous meta-analysis.[@b10-ott-9-1033]

Ethnicity is an important biological factor that might influence VDR function through gene--gene interaction. In our analysis, the association of TaqI polymorphism with a PCa risk was observed in the Asian population, which was consistent with Yin et al[@b10-ott-9-1033] Although the underlying mechanism for the observed ethnic difference in the PCa risk must still be elucidated, a tumor-protective effect of the TaqI t allele in Asians was significantly more pronounced than in the other two ethnic groups, Caucasians and Africans. In the Asian population, a tt genotype carrier had a lower risk of PCa, compared to a TT or TT/Tt genotype.

We also performed tumor stage and Gleason score striated analyses. Differently from Yin et al's study,[@b10-ott-9-1033] we obtained some positive results. We found that the t allele and the tt genotype could reduce the PCa risk when compared with the T allele, TT genotype, or TT/Tt genotype, indicating that variant the TaqI t allele might indeed be associated with disease progression. However, the Gleason score striated analysis indicated no association between TaqI polymorphism and PCa risk.

Study limitations
=================

Although our study showed some positive results, this meta-analysis had several limitations that should be taken consideration when assessing the results. First, although we performed subgroup analyses stratified by ethnicity, tumor stage, and the Gleason score, heterogeneity of TaqI polymorphism among the studies still exists, which suggested that other potential confounding factors were present in the included studies, such as genotyping error, selection bias, population-specific gene--gene or gene--environment interaction, allelic heterogeneity, and chance.[@b41-ott-9-1033],[@b42-ott-9-1033] Although evidence for heterogeneity exists, the sensitivity analysis indicated that studies contributing to the heterogeneity did not significantly affect the estimate of the overall OR. Second, the overall outcomes were based on unadjusted effect estimates. Although the cases and controls were matched for age, sex, and residence in all studies, these confounding factors could slightly modify the effective estimates and a more precise evaluation would have to be adjusted for the potentially suspicious factors. Third, benign prostate hyperplasia was used as control in some included studies, which could affect the pooled results to a varying degree. Finally, in some pooled analyses such as Gleason score striated analysis, the number of included studies was too small, so further relevant studies should be performed in the future so that a stronger conclusion could be drawn.

Conclusion
==========

In summary, a strong association was observed between VDR TaqI genetic polymorphism and PCa, and therefore, TaqI genetic polymorphism may be valuable as a biomarker, especially in Asians. Considering that the quality and quantity of the reviewed articles were limited, larger, well-designed studies should be used in the future to further confirm the association between TaqI genetic polymorphism and PCa.

Supplementary materials
=======================

###### 

Characteristics and quality assessment of eligible studies in meta-analysis

  Study                                  Country                      Ethnicity            Study design                       Genotyping method   Quality indicators from Newcastle--Ottawa Scale   H--w test
  -------------------------------------- ---------------------------- -------------------- ---------------------------------- ------------------- ------------------------------------------------- -----------
  Taylor et al[@b6-ott-9-1033]           USA                          Caucasian, African   Hospital based                     RFLP-PCR            6                                                 Yes
  Kibel et al[@b19-ott-9-1033]           USA                          Caucasian, African   Hospital based                     PCR-RFLP            7                                                 Yes
  Ma et al[@b20-ott-9-1033]              USA                          Caucasian            Nested in PHS cohort study         PCR-RFLP            7                                                 Yes
  Correa-Cerro et al[@b21-ott-9-1033]    Germany                      Caucasian            Hospital based                     PCR-RFLP            6                                                 Yes
  Watanabe et al[@b22-ott-9-1033]        Japan                        Asian                Hospital based                     PCR-RFLP            6                                                 No
  Furuya et al[@b23-ott-9-1033]          Japan                        Asian                Hospital based                     PCR-RFLP            6                                                 Yes
  Habuchi et al[@b24-ott-9-1033]         Japan                        Asian                Hospital based                     PCR-RFLP            6                                                 Yes
  Blazer et al[@b25-ott-9-1033]          USA                          Caucasian, African   Community based                    PCR-RFLP            8                                                 No
  Hamasaki et al[@b3-ott-9-1033]         Japan                        Asian                Hospital based                     PCR-RFLP            6                                                 Yes
  Medeiros et al[@b26-ott-9-1033]        Portugal                     Caucasian            Hospital based                     PCR-RFLP            6                                                 Yes
  Gsur et al[@b27-ott-9-1033]            Austria                      Caucasian            Hospital based                     PCR-RFLP            7                                                 Yes
  Tayeb et al[@b28-ott-9-1033]           UK                           Caucasian            Selected from pathology database   PCR-SSCP            6                                                 Yes
  Tayeb et al[@b29-ott-9-1033]           UK                           Caucasian            Hospital based                     PCR-RFLP            6                                                 Yes
  Maistro et al[@b30-ott-9-1033]         Brazil                       Caucasian, African   Population based                   PCR-RFLP            6                                                 Yes
  Bodiwala et al[@b31-ott-9-1033]        UK                           Caucasian            Hospital based                     PCR-RFLP            6                                                 Yes
  Oakley-Girvan et al[@b32-ott-9-1033]   USA                          Caucasian, African   Population based                   PCR-RFLP            6                                                 Yes
  Huang et al[@b33-ott-9-1033]           Taiwan                       Asian                Hospital based                     PCR-RFLP            6                                                 Yes
  John et al[@b34-ott-9-1033]            USA                          Caucasian            Population based                   PCR-RFLP            6                                                 Yes
  Andersson et al[@b35-ott-9-1033]       Sweden                       Caucasian            Hospital based                     PCR-RFLP            6                                                 Yes
  Chaimuangraj et al[@b36-ott-9-1033]    Thailand                     Asian                Hospital based                     PCR-RFLP            6                                                 Yes
  Holick et al[@b4-ott-9-1033]           USA                          African, Caucasian   Population based                   PCR-SSCP            6                                                 Yes
  Onen et al[@b37-ott-9-1033]            Turkey                       Caucasian            Hospital based                     PCR-RFLP            6                                                 Yes
  Onsory et al[@b38-ott-9-1033]          India                        Indian               Hospital based                     PCR-SSCP            6                                                 Yes
  Rowland et al[@b14-ott-9-1033]         American                     African, Caucasian   Population based                   PCR-RFLP            6                                                 Yes
  Hu et al[@b15-ott-9-1033]              People's Republic of China   Asian                Hospital based                     Real-time PCR       6                                                 Yes
  Yousaf et al[@b16-ott-9-1033]          Pakistan                     Asian                Hospital based                     PCR-SSCP            6                                                 Yes
  Jingwi et al[@b17-ott-9-1033]          American                     Caucasian            Hospital based                     Real-time PCR       6                                                 Yes

**Abbreviations:** H-w, Hardy-Weinberg; RFLP, restriction fragment length polymorphism; PCR, polymerase chain reaction; SSCP, single-strand conformation polymorphism.

###### 

Distribution of TaqI allele and genotype

  Study                                  Group   Allele   Genotype                               
  -------------------------------------- ------- -------- ---------- ------- ------- ----- ----- -----
  Taylor et al[@b6-ott-9-1033]           Case    216      130        86      108     31    68    9
  Control                                340     187      153        170     54      79    37    
  Kibel et al[@b19-ott-9-1033]           Case    82       54         28      41      19    16    6
  Control                                82      48       34         41      15      18    8     
  Ma et al[@b20-ott-9-1033]              Case    744      454        290     372     134   186   52
  204 control                            1,178   707      471        589     204     299   86    
  Correa-Cerro et al[@b21-ott-9-1033]    Case    212      135        77      106     48    39    19
  Control                                190     116      74         95      32      52    11    
  Watanabe et al[@b22-ott-9-1033]        Case    200      178        22      100     80    18    2
  Control                                404     356      48         202     160     36    6     
  Furuya et al[@b23-ott-9-1033]          Case    132      107        25      66      41    25    0
  Control                                120     100      20         60      41      18    1     
  Habuchi et al[@b24-ott-9-1033]         Case    444      396        48      222     176   44    2
  Control                                674     587      87         337     253     81    3     
  Blazer et al[@b25-ott-9-1033]          Case    154      88         66      77      24    40    13
  Control                                366     212      154        183     68      76    39    
  Hamasaki et al[@b3-ott-9-1033]         Case    230      204        26      115     91    22    2
  Control                                266     216      50         133     91      34    8     
  Medeiros et al[@b26-ott-9-1033]        Case    324      195        129     162     52    91    19
  Control                                412     238      174        206     73      92    41    
  Gsur et al[@b27-ott-9-1033]            Case    380      227        153     190     71    85    34
  Control                                380     249      131        190     81      87    22    
  Tayeb et al[@b28-ott-9-1033]           Case    42       24         18      21      7     10    4
  Control                                758     453      305        379     136     181   62    
  Tayeb et al[@b29-ott-9-1033]           Case    56       52         4       28      25    2     1
  Control                                112     83       29         56      32      19    5     
  Maistro et al[@b30-ott-9-1033]         Case    330      202        128     165     60    82    23
  Control                                400     272      128        200     95      82    23    
  Bodiwala et al[@b31-ott-9-1033]        Case    736      444        292     368     133   178   57
  Control                                486     285      201        243     80      125   38    
  Oakley-Girvan et al[@b32-ott-9-1033]   Case    690      418        272     345     124   170   51
  Control                                584     365      219        292     115     135   42    
  Huang et al[@b33-ott-9-1033]           Case    320      306        14      160     146   14    0
  Control                                410     384      26         205     179     26    0     
  John et al[@b34-ott-9-1033]            Case    848      528        320     424     164   200   60
  Control                                872     506      366        436     153     200   83    
  Andersson et al[@b35-ott-9-1033]       Case    274      164        110     137     51    62    24
  Control                                352     212      140        176     67      78    31    
  Chaimuangraj et al[@b36-ott-9-1033]    Case    56       50         6       28      22    6     0
  Control                                148     132      16         74      59      14    1     
  Holick et al[@b4-ott-9-1033]           Case    1,172    730        442     586     238   254   94
  Control                                1,090   648      442        545     188     272   85    
  Onen et al[@b37-ott-9-1033]            Case    266      180        86      133     62    56    15
  Control                                314     189      125        157     57      75    25    
  Onsory et al[@b38-ott-9-1033]          Case    200      150        50      100     55    40    5
  Control                                200     134      66         100     43      48    9     
  Rowland et al[@b14-ott-9-1033]         Case    3,252    2,172      1,080   1,626   732   708   186
  Control                                2,144   1,376    768        1,072   451     474   147   
  Hu et al[@b15-ott-9-1033]              Case    216      202        14      108     96    10    2
  Control                                484     460      24         242     219     22    1     
  Yousaf et al[@b16-ott-9-1033]          Case    88       67         21      44      27    13    4
  Control                                238     163      75         119     76      11    32    
  Jingwi et al[@b17-ott-9-1033]          Case    612      451        161     306     170   111   25
  Control                                502     325      177        251     105     115   31    
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###### 

ORs of prostate cancer associated with VDR TaqI polymorphisms.

**Notes:** (**A**) T vs t, (**B**) TT vs tt, and (**C**) (TT/Tt) vs tt. Weights are from random effects analysis.

**Abbreviations:** OR, odds ratio; VDR, vitamin D receptor; CI, confidence interval.
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###### 

ORs of prostate cancer associated with TaqI polymorphism in different populations.

**Notes:** (**A**) T vs t and (**B**) (TT/Tt) vs tt. Weights are from random effects analysis.

**Abbreviations:** OR, odds ratio; CI, confidence interval.
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###### 

ORs of TaqI polymorphism comparing advanced prostate cancer group with control group.

**Notes:** (**A**) T vs t, (**B**) TT vs tt, and (**C**) (TT/Tt) vs tt. Weights are from random effects analysis.

**Abbreviations:** OR, odds ratio; CI, confidence interval.
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###### 

Detailed association of VDR TaqI polymorphism with PCa risk in each individual study

  Study                                  OR (95% CI)                                                                         
  -------------------------------------- -------------------- -------------------- -------------------- -------------------- --------------------
  Taylor et al[@b6-ott-9-1033]           1.24 (0.88--1.75)    2.36 (1.01--5.53)    0.67 (0.39--1.54)    0.86 (0.51--1.47)    3.06 (1.41--6.63)
  Kibel et al[@b19-ott-9-1033]           1.37 (0.73--2.57)    1.69 (0.48--5.93)    1.43 (0.55--3.70)    1.50 (0.62--3.62)    1.41 (0.44--4.51)
  Ma et al[@b20-ott-9-1033]              1.04 (0.86--1.26)    1.09 (0.72--1.63)    1.06 (0.80--1.40)    1.06 (0.81--1.39)    1.05 (0.72--1.53)
  Correa-Cerro et al[@b21-ott-9-1033]    1.12 (0.75--1.68)    0.87 (0.37--2.07)    2.00 (1.09--3.68)    1.63 (0.92--2.89)    0.60 (0.27--1.34)
  Watanabe et al[@b22-ott-9-1033]        1.09 (0.64--1.86)    1.50 (0.30--7.60)    1.00 (0.54--1.87)    1.05 (0.58--1.91)    1.50 (0.30--7.57)
  Furuya et al[@b23-ott-9-1033]          0.86 (0.45--1.64)    --                   0.72 (0.34--1.52)    0.76 (0.36--1.59)    --
  Habuchi et al[@b24-ott-9-1033]         1.22 (0.84--1.78)    1.04 (0.17--6.31)    1.28 (0.85--1.94)    1.27 (0.85--1.91)    0.99 (0.16--5.96)
  Blazer et al[@b25-ott-9-1033]          0.97 (0.66--1.42)    1.06 (0.49--2.31)    0.67 (0.37--1.23)    0.77 (0.43--1.35)    1.33 (0.67--2.67)
  Hamasaki et al[@b3-ott-9-1033]         1.82 (1.09--3.03)    4.00 (0.83--19.35)   1.55 (0.84--2.84)    1.75 (0.98--3.12)    3.62 (0.75--17.39)
  Medeiros et al[@b26-ott-9-1033]        1.11 (0.82--1.49)    1.54 (0.80--2.94)    0.72 (0.46--1.14)    0.86 (0.56--1.33)    1.87 (1.04--3.37)
  Gsur et al[@b27-ott-9-1033]            0.78 (0.58--1.05)    0.57 (0.30--1.06)    0.90 (0.58--1.39)    0.80 (0.53--1.21)    0.60 (0.34--1.07)
  Tayeb et al[@b28-ott-9-1033]           0.90 (0.48--1.68)    0.80 (0.23--2.83)    0.93 (0.35--2.51)    0.89 (0.35--2.27)    0.83 (0.27--2.55)
  Tayeb et al[@b29-ott-9-1033]           4.54 (1.51--13.66)   3.91 (0.43--35.60)   7.42 (1.58--34.90)   6.25 (1.69--23.15)   2.65 (0.29--23.82)
  Maistro et al[@b30-ott-9-1033]         0.74 (0.55--1.01)    0.63 (0.33--1.23)    0.63 (0.41--0.99)    0.63 (0.41--0.96)    0.80 (0.43--1.49)
  Bodiwala et al[@b31-ott-9-1033]        1.07 (0.85--1.35)    1.11 (0.68--1.82)    1.17 (0.82--1.67)    1.15 (0.82--1.62)    1.01 (0.65--1.58)
  Oakley-Girvan et al[@b32-ott-9-1033]   0.92 (0.74--1.16)    0.89 (0.55--1.44)    0.86 (0.61--1.20)    0.86 (0.63--1.19)    0.97 (0.62--1.51)
  Huang et al[@b33-ott-9-1033]           1.48 (0.76--2.88)    --                   1.51 (0.76--3.01)    --                   --
  John et al[@b34-ott-9-1033]            1.19 (0.98--1.45)    1.48 (1.00--2.21)    1.07 (0.80--1.44)    1.17 (0.88--1.54)    1.43 (0.99--2.05)
  Andersson et al[@b35-ott-9-1033]       0.99 (0.71--1.36)    0.98 (0.52--1.88)    0.96 (0.58--1.57)    0.97 (0.61--1.53)    1.01 (0.56--1.81)
  Chaimuangraj et al[@b36-ott-9-1033]    1.01 (0.37--2.73)    --                   0.87 (0.30--2.55)    0.93 (0.32--2.71)    --
  Holick et al[@b4-ott-9-1033]           1.13 (0.95--1.33)    1.15 (0.81--1.63)    1.36 (1.05--1.75)    1.30 (1.02--1.65)    0.97 (0.70--1.33)
  Onen et al[@b37-ott-9-1033]            1.38 (0.98--1.95)    1.81 (0.87--3.78)    1.46 (0.88--2.40)    1.53 (0.96--2.45)    1.49 (0.75--2.96)
  Onsory et al[@b38-ott-9-1033]          1.48 (0.96--2.28)    2.30 (0.72--7.37)    1.54 (0.86--2.74)    1.62 (0.93--2.83)    1.88 (0.61--5.82)
  Rowland et al[@b14-ott-9-1033]         1.12 (1.00--1.26)    1.283 (1.00--1.64)   1.09 (0.92--1.28)    1.13 (0.97--1.32)    1.23 (0.98--1.55)
  Hu et al[@b15-ott-9-1033]              0.77 (0.39--1.52)    0.22 (0.20--2.45)    0.96 (0.44--2.11)    0.84 (0.40--1.76)    0.22 (0.02--2.45)
  Yousaf et al[@b16-ott-9-1033]          1.47 (0.84--2.57)    2.84 (0.92--8.78)    0.30 (0.12--0.75)    0.90 (0.44--1.83)    3.68 (1.22--11.10)
  Jingwi et al[@b17-ott-9-1033]          1.53 (1.18--1.97)    2.01 (1.12--3.59)    1.68 (1.17--2.40)    1.74 (1.24--2.44)    1.58 (0.91--2.76)

**Abbreviations:** VDR, vitamin D receptor; PCa, prostate cancer; OR, odds ratio; CI, confidence interval.

###### 

Meta-analysis of the association of VDR gene TaqI polymorphism with PCa risk

  Gene            Studies   Test for overall effect   Heterogeneity   Public bias                           
  --------------- --------- ------------------------- --------------- ------------- ------- ------- ------- -------
  T vs t          27        1.11 (1.03--1.21)         2.64            0.008         36.9%   0.029   0.478   0.423
  TT vs Tt        27        1.07 (0.94--1.22)         1.05            0.296         49%     0.002   0.835   0.550
  TT vs tt        24        1.19 (1.01--1.42)         2.06            0.040         34.4%   0.051   0.673   0.724
  TT vs (tt/Tt)   26        1.10 (0.99--1.24)         1.73            0.084         41.5%   0.015   0.692   0.949
  (TT/Tt) vs tt   24        1.18 (1.02--1.38)         2.15            0.031         31.4%   0.072   0.673   0.460

**Abbreviations:** VDR, vitamin D receptor; PCa, prostate cancer; OR, odds ratio; CI, confidence interval.

###### 

Meta-analysis of the association of VDR gene TaqI polymorphism with PCa risk in different populations

  Gene             Studies   Test for overall effect   Heterogeneity                                    Public bias                                                                                                         
  ---------------- --------- ------------------------- ------------------------------------------------ ------------------------------------------------- ------- ------- ------------------------------------------------- -------------------------------------------------
  Caucasian                                                                                                                                                                                                                 
   T vs t          13        1.06 (0.97--1.17)         1.31                                             0.191                                             22.9%   0.212   0.583                                             0.474
   TT vs Tt        13        1.02 (0.86--1.21)         0.24                                             0.898                                             46.2%   0.034   0.855                                             0.842
   TT vs tt        13        1.14 (0.97--1.33)         1.55                                             0.122                                             2.1%    0.425   0.583                                             0.737
   TT vs (tt/Tt)   13        1.04 (0.90--1.21)         0.55                                             0.579                                             36.6%   0.090   0.360                                             0.814
   (TT/Tt) vs tt   14        1.13 (0.94--1.35)         1.26                                             0.208                                             28.6%   0.150   0.511                                             0.648
  African                                                                                                                                                                                                                   
   T vs t          5         1.04 (0.85--1.28)         0.42[a](#tfn3-ott-9-1033){ref-type="table-fn"}   0.676[a](#tfn3-ott-9-1033){ref-type="table-fn"}   0.0%    0.956   0.806[a](#tfn3-ott-9-1033){ref-type="table-fn"}   0.917[a](#tfn3-ott-9-1033){ref-type="table-fn"}
   TT vs Tt        5         0.97 (0.74--1.29)         0.18[a](#tfn3-ott-9-1033){ref-type="table-fn"}   0.858[a](#tfn3-ott-9-1033){ref-type="table-fn"}   0.0%    0.558   0.221[a](#tfn3-ott-9-1033){ref-type="table-fn"}   0.854[a](#tfn3-ott-9-1033){ref-type="table-fn"}
   TT vs tt        5         1.22 (0.75--1.97)         0.80[a](#tfn3-ott-9-1033){ref-type="table-fn"}   0.421[a](#tfn3-ott-9-1033){ref-type="table-fn"}   0.0%    0.844   0.806[a](#tfn3-ott-9-1033){ref-type="table-fn"}   0.935[a](#tfn3-ott-9-1033){ref-type="table-fn"}
   TT vs (tt/Tt)   5         1.01 (0.78--1.32)         0.08[a](#tfn3-ott-9-1033){ref-type="table-fn"}   0.933[a](#tfn3-ott-9-1033){ref-type="table-fn"}   0.0%    0.805   0.462[a](#tfn3-ott-9-1033){ref-type="table-fn"}   0.781[a](#tfn3-ott-9-1033){ref-type="table-fn"}
   (TT/Tt) vs tt   6         1.32 (0.94--1.87)         1.59                                             0.112                                             0.0%    0.808   0.368                                             0.366
  Asian                                                                                                                                                                                                                     
   T vs t          9         1.27 (1.06--1.52)         2.56                                             0.010                                             0.0%    0.527   0.175                                             0.308
   TT vs Tt        9         1.07 (0.81--1.43)         0.49                                             0.627                                             39.1%   0.107   0.059                                             0.088
   TT vs tt        6         1.44 (0.59--3.51)         0.80                                             0.426                                             59.7%   0.030   0.452                                             0.969
   TT vs (tt/Tt)   8         1.19 (0.96--1.47)         1.58                                             0.115                                             0.0%    0.517   0.063                                             0.153
   (TT/Tt) vs tt   6         1.93 (1.02--3.66)         2.02                                             0.043                                             11.8%   0.340   0.054                                             0.067

**Note:**

Jingwi et al's study[@b17-ott-9-1033] was excluded.

**Abbreviations:** VDR, vitamin D receptor; PCa, prostate cancer; OR, odds ratio; CI, confidence interval.

###### 

Meta-analysis of the association of VDR gene TaqI polymorphism with PCa risk in different tumor stages

  Stage                 Studies   Test for overall effect   Heterogeneity   Public bias                           
  --------------------- --------- ------------------------- --------------- ------------- ------- ------- ------- -------
  Local vs control                                                                                                
   T vs t               5         1.09 (0.95--1.25)         1.18            0.237         0.0%    0.939   0.806   0.741
   TT vs tt             2         1.26 (0.91--1.73)         1.40            0.160         0.0%    0.635   --      --
   TT vs Tt             5         0.97 (0.80--1.18)         0.32            0.752         0.0%    0.941   0.806   0.213
   TT vs (tt/Tt)        6         1.07 (0.88--1.31)         0.68            0.498         3.3%    0.395   1.000   0.885
   (TT/Tt) vs tt        4         1.16 (0.88--1.53)         1.07            0.287         0.0%    0.451   0.734   0.442
  Advanced vs control                                                                                             
   T vs t               6         1.20 (1.01--1.42)         2.05            0.040         31.5%   0.199   0.452   0.354
   TT vs tt             4         1.34 (1.08--1.67)         0.63            0.009         0.0%    0.746   0.734   0.216
   TT vs Tt             6         1.15 (0.86--1.52)         0.93            0.352         45.6%   0.101   0.707   0.799
   TT vs (tt/Tt)        7         1.17 (0.89--1.54)         1.14            0.256         43.6%   0.100   0.368   0.941
   (TT/Tt) vs tt        6         1.28 (1.05--1.56)         2.44            0.015         0.0%    0.821   0.420   0.189
  Local vs advanced                                                                                               
   T vs t               5         0.95 (0.82--1.10)         0.65            0.515         0.0%    0.536   0.462   0.191
   TT vs tt             2         1.02 (0.72--1.45)         0.13            0.896         0.0%    0.663   --      --
   TT vs Tt             5         0.76 (0.48--1.21)         1.14            0.255         32.9%   0.202   0.806   0.575
   TT vs (tt/Tt)        6         0.87 (0.62--1.21)         0.84            0.400         14.0%   0.325   0.260   0.805
   (TT/Tt) vs tt        4         1.01 (0.74--1.38)         0.08            0.938         0.0%    0.628   0.734   0.054

**Abbreviations:** VDR, vitamin D receptor; PCa, prostate cancer; OR, odds ratio; CI, confidence interval.
